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HerpesvirusMicroRNAs (miRNAs) are the subject of enormous interest. They are small non-coding RNAs that play a
regulatory role in numerous and diverse cellular processes such as immune function, apoptosis and
tumorigenesis. Several virus families have been shown to encode miRNAs, and an appreciation for their roles
in the viral infectious cycle continues to grow. Despite the identiﬁcation of numerous (N225) viral miRNAs, an
in depth functional understanding of most virus-encoded miRNAs is lacking. Here we focus on a few viral
miRNAs with well-deﬁned functions. We use these examples to extrapolate general themes of viral miRNA
activities including autoregulation of viral gene expression, avoidance of host defenses, and a likely important
role in maintaining latent and persistent infections. We hypothesize that although the molecular mechanisms
and machinery are similar, the majority of viral miRNAs may utilize a target strategy that differs from host
miRNAs. That is, many viral miRNAs may have evolved to regulate viral-encoded transcripts or networks of
host genes that are unique to viral miRNAs. Included in this latter category is a likely abundant class of viral
miRNAs that may regulate only one or a few principal host genes. Key steps forward for the ﬁeld are discussed,
including the need for additional functional studies that utilize surgical viral miRNA mutants combined with
relevant models of infection..de (A. Grundhoff), Chris_sullivan@mail.utexas.edu (C.S.
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Discovery of miRNAs
Originally called small temporal RNAs (stRNAs) for the roles the
founding members played in regulating the proper timing of
developmental events, miRNAs were ﬁrst discovered in 1993 by
Ambros and colleagues in the laboratory model organism nematode
Ceanorhabditis elegans (C. elegans) (Lee et al., 1993). Using genetic
studies, it was demonstrated that a small RNA derived from a hairpin
structure had potent negative trans-regulatory ability by binding to
the 3′ UTR of other transcripts (Reinhart et al., 2000). Originally
thought to be an oddity of nematodes, it was later demonstrated that
at least some C. elegans miRNAs are conserved with other metazoans
including humans (Pasquinelli et al., 2000). In 2001, three landmark
papers were published in a single issue of Science that described over
a hundred miRNAs (some evolutionarily conserved) that are found in
diverse metazoan cells (Lagos-Quintana et al., 2001; Lau et al., 2001;
Lee and Ambros, 2001). These studies launched a revolution in our
understanding of gene regulation that continues to expand with
currently over 1000 papers on miRNAs being published each year
(source ISI web of Science, over 1000 papers published each year since
2008 with “microRNA” used as the topic search term).
Biogenesis
Because viral miRNAs mostly utilize the same processing and
effector machinery as host miRNAs, and excellent reviews have
already be written on this subject (Bartel, 2004; Carthew and
Sontheimer, 2009; Kim, 2005), we provide only a brief overview of
biogenesis here. miRNAs are derived from primary transcripts (pri-
miRNAs), typically hundreds to thousands of nucleotides long, that
undergo a series of endonucleolytic processing and shuttling events to
give rise to a ﬁnal ~22 nucleotide effector molecule. Most pri-miRNAs
are transcribed by RNA polymerase II (pol II); hence, similar to protein
coding mRNAs, their transcription is regulated by proteinaceous
transcription factors, they are processed to the display typical 7-
methyl guanosine cap structures as well as polyA tails, and they can
undergo splicing reactions. The vast majority of pri-miRNAs contain at
least one ~80 nucleotide hairpin secondary structure that can be
intronic or exonic. The hairpin portion of the pri-miRNA is recognized
by Microprocessor, a multi-protein nuclear complex containing the
RNaseIII-like enzyme Drosha. Drosha-mediated double-stranded
cleavage of a bottom portion of the stem (away from the terminal
loop) “liberates” an ~60 nucleotide hairpin called a precursor miRNA
(pre-miRNA), which is recognized by the RAN-GTPase Exportin5
complex and exported to the cytoplasm (Lee et al., 2003; Zeng et al.,
2005).
Once in the cytoplasm, the terminal loop portion of the pre-miRNA
is removed by the RNaseIII-like enzyme Dicer (Bernstein et al., 2001;
Hutvagner et al., 2001), leaving a transient, partially complementary,
double-stranded siRNA-like molecule. One strand of this molecule
becomes stably incorporated into the multi-protein RNA induced
silencing complex (RISC), where it serves to guide RISC to the mRNA
transcript targets. RISC-bound miRNAs bind to mRNA targets with
partial base pair complementarity, typically in the 3′ untranslated
region (UTR) (Grimson et al., 2007). RISC-bound transcripts produce
less protein due to molecular mechanisms which are still ill deﬁned
(Bartel, 2009). Frequently, but not always, this inhibition is associated
with transcript destabilization of sufﬁcient magnitude to be picked up
in high-throughput analysis methods such as microarrays (Lim et al.,
2005). Hence, analysis of mRNA steady state levels can sometimes be
utilized to ﬁsh out miRNA-targeted transcripts. Although uncommon
in animals, some viral and most plant miRNAs bind to their mRNA
targets with perfect complementarity, and similar to siRNAs, cause a
speciﬁc, irreversible endonucleolytic cleavage event in the targettranscript. One unresolved mystery is why this mode of miRNA-
mediated regulation is so rarely used by animal host miRNAs.Some key functions of host miRNAs and their mode of action
Originally identiﬁed as modulators of developmental timing, host
miRNAs have now been shown to affect numerous other diverse
processes including (just to name a few) cell fate determination
(Johnston and Hobert, 2003), neuronal plasticity (Schratt et al.,
2006), cholesterol metabolism (Krutzfeldt et al., 2005), and
processes of obvious “virological relevance” such as the innate and
adaptive immune responses (Lodish et al., 2008 and references
therein), apoptosis (Subramanian and Steer, 2010 and references
therein), cell cycle (Kedde et al., 2010), and tumorigenesis (Medina
and Slack, 2008 and references therein). Bioinformatics and
experimental approaches have led to a model whereby ~30–75% of
different mRNA transcripts are regulated by miRNAs, with each
miRNA potentially regulating hundreds of transcripts (Bartel, 2009).
This sets up a complex web of potential regulatory interactions.
For example, the human genome encodes over 900 pre-miRNAs
(Grifﬁths-Jones, 2006), allowing for some mRNAs to be regulated by
multiple miRNAs. In this model, a network of speciﬁc transcripts and
the multiple miRNAs they interact with, combine to modulate a
particular biological outcome (Fig. 1).
Although our understanding of what dictates speciﬁc interactions
between miRNA and target is still imperfect, it is clear that for many
miRNA–target pairs, the 5′ end of a miRNA plays an especially
important role in dictating target speciﬁcity. Nucleotides 2–8, or
minimally 2–7 (numbering starting from the 5′ end of the miRNA)
comprise the so-called “seed” region (reviewed in Bartel, 2009). The
seed region often binds to target mRNAs in their 3′ UTR with perfect
complementarity. Thus, miRNA overexpression or inhibition, com-
bined with cDNAmicroarray analysis and computational analysis, can
identify some bona ﬁde miRNA–mRNA target interactions. Of course,
there are caveats to this approach including the observation that not
all miRNA–target interactions display perfect seed complementarity
(Didiano and Hobert, 2006) and not all miRNAs bind to their targets in
the 3′UTR (Grey et al., 2010). Furthermore, not all miRNA–target
interactions result in robust, measurable decreases in target transcript
steady state levels. Despite the numerous exceptions, mounting
evidence suggests that manymiRNA–target interactions are mediated
by perfect seed complementarity between miRNA and the 3′UTR of
target transcripts (Grimson et al., 2007).Identiﬁcation of viral miRNAs
Most viral miRNAs had initially been identiﬁed by a protocol
previously developed for the identiﬁcation of host-encoded miRNAs,
a procedure that involves RNA size fractionation, ligation of linkers,
reverse transcription, concatamerization, and Sanger sequencing.
We and others have also developed computational approaches that
rely on commonalities in the predicted secondary structures of pre-
miRNAs to identify miRNA-encoding loci speciﬁcally in viral
genomes (Grundhoff et al., 2006; Pfeffer et al., 2005; Sullivan et al.,
2005). While such ab initio prediction approaches often produce
signiﬁcant numbers of false positives that have to be eliminated
experimentally, they have the advantage of being able to identify the
less abundantly expressed miRNAs which frequently had been
overlooked in the original cloning protocol. However, with the
advent of massively parallel sequencing technologies it is now
possible to explore libraries of cloned small RNAs with unprece-
dented depth; as a consequence, the bioinformatic prediction of
potential pre-miRNA hairpin structures is nowadays rarely used for
other than conﬁrmatory purposes.
Fig. 1.Model for microRNA-mediated regulation. mRNAs are depicted as white circles (the 5′ cap) extending to the 3′ poly A tails (AAA…), miRNAs are depicted as being associated
with the RNA induced silencing complex (RISC) with their important target binding determinant region (the “seed” region, nucleotides 2–8) depicted in color. The respective
miRNA/RISC docking site is shown as a color-matched bar in 3′ UTR of the mRNA transcripts. This hypothetical example demonstrates several points thought to be common in many
miRNA-regulated networks. mRNAs 1–4 play a role in biological process 1, mRNAs 5–7 play a role in biological process 2. Note that several different miRNAs can regulate a single
mRNA and conversely several different mRNAs are regulated by one miRNA. In addition, the same mRNA target can contain multiple miRNA docking sites for the same miRNA, as
shown for mRNA 7. Combined, these features allow for ﬁne-tuning regulation of gene expression. Typically, the more miRNAs regulating a transcript, the greater the degree of
repression. A single miRNA can regulate hundreds of mRNA targets and can play a role in regulating different biological functions. This role can serve to regulate the amount of or the
timing of gene expression. mRNA 5 can trigger a negative feedback loop of its own expression as it induces increased autoregulatory miRNA levels. Positive feed-forward loops (not
depicted) also occur. Note, the potential for extensive cross talk between miRNAs and targets (and this is likely a gross oversimpliﬁcation as there are greater than 900 human
miRNAs known with ~hundreds of different ones being expressed in any single cell type at a given time). Furthermore, conservative estimates suggest 30%, but perhaps as many as
70% of transcripts (or more) are regulated by miRNAs. The overall picture emerging is that of complex, interlaced, regulatory networks that can serve as rheostats to ﬁnely regulate
gene expression. Virus-encoded miRNA regulation offers several advantages to the virus including: the ability to regulate hundreds of transcripts, non-immunogenicity (since no
proteins are required to be made by the virus), and a relatively small amount of genomic space.
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For this section please refer to Fig. 2 and Table 1. In 2004, Pfeffer
and colleagues published the ﬁrst report describing the cloning of
viral-encoded miRNAs from a cell line infected with Epstein–Barr
virus (EBV) (Pfeffer et al., 2004). EBV is a member of the Herpesviridae
in the gamma sub-family and is associated with several tumors in its
human host, including Burkitt's lymphoma, Hodgkin's disease and
nasopharyngeal carcinoma. Notably, EBV also efﬁciently transforms
primary B cells in vitro, giving rise to the so-called lymhoblastoid cell
lines (LCLs). The proliferation of LCLs is driven by the expression of at
least 9 viral proteins, some of which (e.g. latent membrane protein 1,
LMP1) also exhibit transforming potential in mice. However, most
EBV-associated tumors express a more restricted repertoire of viral
proteins (in Burkitt's lymphoma, usually only a single viral protein
without known oncogenic potential is expressed), and the pathogen-
esis of these tumors hence is likely to be much more complex
(reviewed in Bornkamm, 2009).
Initially, Pfeffer and colleagues identiﬁed 5 EBV-encoded pre-
miRNAs in B95-8 cells, an LCL generated by the in vitro infection of
marmoset B cells (Pfeffer et al., 2004). Subsequent studies revealedFig. 2. Virus families that encodemicroRNAs ormicrorna-likemolecules. Depicted are cartoon
encode miRNAs. Indicated is the number of distinct pre-miRNAs reported for each family. Th
from at least 15 different viruses. All herpesviruses that are known to encode miRNAs, e
Polyomaviridae are known to encode a single pre-miRNA. Some members of the adenovirid
RNAs. miRNA biogenesis from VA RNAs does not utilize Drosha. These atypical pre-miRNAs ar
efﬁciency), but nonetheless make up the most abundant miRNAs present in the cell due to
insect viruses, an ascovirus and a baculovirus, are known to encode a pre-miRNA. There hav
encodes pre-miRNAs. These reports have not been independently veriﬁed and their existennumerous additional pre-miRNAs encoded by EBV such that, today,
EBV is known to encode a total of 25 pre-miRNAs (Cai et al., 2006b;
Grundhoff et al., 2006; Zhu et al., 2009), which produce at least 44
mature miRNA species (see Table 1). Indeed, most of these miRNAs
had been missed in the initial study due to the fact that they are
located in a region that is deleted from the genome of the B95-8 EBV
strain. Since the B95-8 laboratory strain of EBV efﬁciently transforms
primary B cells, the deleted miRNAs are clearly not required for
growth transformation in vitro. However, one cannot conclude from
this observation that these miRNAs do not contribute to tumorigen-
esis in vivo; the fact that the known ﬁeld strains as well as tumor-
derived EBV strains retain the deleted miRNA-coding segment points
towards an important function of this genomic region.
With the beneﬁt of hindsight it may not be surprising that EBVwas
found to encode miRNAs, since the majority of herpesviruses appear
to do so. Indeed, more than 95% of the viral miRNAs known today are
of herpesvirus origin (see Table 1). This superiority in numbers is also
due to the fact that, even considering their considerable genome size,
individual herpesviruses tend to express rather large numbers of
miRNAs (some family members encode clusters with more than 30
pre-miRNAs). Taken together, this suggests that miRNAs play andiagrams of virions (not exactly to scale) from virus families that have been reported to
e Herpesviridae encode the most distinct pre-miRNAs, with greater than two hundred
xpress multiple pre-miRNAs (from a ~7 to greater than 25). Several members of the
ae encode two non-canonical pre-miRNA-like molecules, called Virus Associated (VA)
e pol III transcripts that are inefﬁciently processed intomiRNAs (less than 1% processing
the sheer abundance of the VA RNA precursor (107–108 copies per cell). Currently, two
e been several controversial reports purporting that HIV, a member of the retroviridae,
ce is the subject of some debate (Lin and Cullen, 2007). See also Table 1.
Table 1
Virus-encoded miRNAs or miRNA-like molecules.
Virus family or subfamily Virus species Pre-miR hairpins Mature miRs
Alpha-herpesvirinae Herpes Simplex Virus 1 16 25
Herpes Simplex Virus 2 18 24
Herpes B virus 3 3
Herpesvirus of turkeys 17 28
Infectious laryngotracheitis virus 7 10
Bovine herpesvirus 1 10 12
Marek's disease virus type 1 14 26
Marek's disease virus type 2 18 36
Beta-herpesvirinae Human cytomegalovirus 11 17
Mouse cytomegalovirus 18 28
Gamma-herpesvirinae Epstein–Barr virus 25 44
Rhesus lymphocryptovirus 36 50
Kaposi's sarcoma-associated herpesvirus 12 25
Rhesus monkey rhadinovirus 15 25
Mouse gamma herpesvirus 68 15 28
Polyomaviridae Simian virus 40 1 2
JC polyomavirus 1 2
BK polyomavirus 1 2
Mouse polyomavirus 1 2
Merkel cell polyomavirus 1 2
SA12 1 2
Ascoviridae Heliothis virescens ascovirus 1 1
Baculoviridae Bombyx mori nucleopolyhedrosis virus 4 4
Adenoviridae Human adenoviruses types 2 and 5, others? 2a 3
a Pre-miRNA-like molecules.
328 A. Grundhoff, C.S. Sullivan / Virology 411 (2011) 325–343important role in the herpesviral lifecycle. Since herpesviruses exhibit
a biphasic lifecycle and establish long-lasting latent infections, one
important beneﬁt they could gain from employing miRNAs is the
ability to regulate host and/or viral gene expression without
expressing proteinaceous factors that may elicit an antigenic immune
response. This hypothesis is further corroborated by the fact that most
herpesviruses express their miRNAs during latency, even though this
is a stage of the viral lifecycle which is otherwise highly restrictive for
viral gene expression.
The discovery of EBV-encoded miRNAs was followed by reports
from several groups describing the identiﬁcation of a total of 12 pre-
miRNAs encoded by Kaposi sarcoma-associated herpesvirus (KSHV)
(Cai et al., 2005; Grundhoff et al., 2006; Pfeffer et al., 2005; Samols
et al., 2005). KSHV encodes 12 different pre-miRNAs that give rise to
25 different readily detectable miRNAs. Like EBV, KSHV belongs to the
gamma-herpesvirus subfamily, whose members are frequently
associated with tumors in their natural host. KSHV is considered the
etiologic agent of Kaposi's sarcoma, a highly vascularized lesion
comprised mostly of endothelial cells that afﬂicts mainly immuncom-
promised individuals. KSHV infection is also associatedwith rare B cell
hyperproliferative disorders, including Primary Effusion Lymphoma
(PEL) and some forms of Multicentric Castleman's Disease (MCD) (see
Ganem, 2010; Wen and Damania, 2010 for recent reviews). Since
gamma herpesvirus-associated tumorigenesis is always driven by
latently infected cells, an attractive hypothesis is that modulation of
host gene expression by viral miRNAs may causally contribute to
tumorigenic processes. As discussed later, although so far not proven
in animal models, at least for some viral miRNAs the circumstantial
evidence for this theory is very strong.
Additionally, like some other herpesviruses (Buck et al., 2007;
Dolken et al., 2007; Umbach et al., 2008), KSHV encodes several
miRNA derivatives that are encoded exactly antisense relative to the
abundant pre-miRNAs (Lin et al., 2010; Umbach and Cullen, 2009).
Interestingly, the KSHV antisense miRNAs are only detectable in cells
undergoing lytic replication, and are likely derivative of recently
described longer non-translated RNAs that span much of the KSHV
genome (Chandriani et al., 2010; Lin et al., 2010). However, in
contrast to other viral antisense miRNAs that are fairly abundant
(Buck et al., 2007; Dolken et al., 2007; Umbach et al., 2008), the KSHVantisense miRNAs are of extremely low abundance, thus, their
functional relevance remains uncertain. Because of the low abun-
dance of these miRNAs, we do not include them in Table 1 listing the
known viral miRNAs.
As is evident from the list in Table 1, herpesvirus miRNAs are not
only found in the gamma-, but also in the alpha- and beta
herpesvirus subfamilies. With one notable exception (see miR-
155 mimics — viral analogues of a human oncomir? section), alpha-
and beta herpesviruses do not cause tumors in their hosts. They are
nevertheless important pathogens of animals and humans. For
example, the neurotropic alpha herpesviruses Herpes Simplex Virus
1 and 2 (HSV-1 and -2) cause oral or genital herpes lesions, but may
also lead to encephalitis or meningitis. The beta herpesvirus human
cytomegalovirus (HCMV) represents the most signiﬁcant viral
cause of birth defects in industrialized countries and frequently
causes life-threatening disease in immunocompromised indivi-
duals. While not tumorigenic, it is conceivable that viral miRNAs
enhance the virulence of these pathogens and thus contribute to
disease development.
In addition to the herpesviruses, numerous members of the
polyomavirus family, as well as adenoviruses, an ascovirus, and a
baculovirus have been shown to encode miRNAs or miRNA-like
molecules (Aparicio et al., 2006; Cantalupo et al., 2005; Hussain et al.,
2008; Seo et al., 2009, 2008; Singh et al., 2010; Sullivan et al., 2005,
2009). These ﬁndings predict that the viruses most likely to encode
miRNAs will have DNA genomes, nuclear lifecycles, and an ability to
undergo latent and/or persistent infections. Additionally, there have
been several reports suggesting HIV, an RNA virus whose genome is
reverse transcribed and incorporated into the host DNA, may also
encode miRNAs. However, these reports are controversial, with other
labs unable to detect expression of these putative miRNAs (Lin and
Cullen, 2007; Pfeffer et al., 2005). Finally, low or high-throughput
sequencing efforts of RNA from cultured cells infected with any of
several different RNA viruses, including HCV, YFV,WNV, and Inﬂuenza
A failed to identify viral-encoded miRNAs (Pfeffer et al., 2005;
Umbach et al., 2010).
Given the potential beneﬁts afforded to the viral lifecycle by viral-
encoded miRNAs, it remains an enigmatic question as to why more
virus families do not utilize this regulatory strategy. miRNAs take up
329A. Grundhoff, C.S. Sullivan / Virology 411 (2011) 325–343relatively little genomic space, presumably are non-immunogenic,
and each has the potential to regulate numerous host and/or viral
transcripts. In addition, one might predict that evolving inverted
hairpins should be a fairly common occurrence in evolutionary time. If
true, why have viral-encoded miRNAs not been discovered in more
virus families? Aside from the obvious reason that many viruses have
yet to be surveyed, there are at least two reasons that could account
for this: lack of access to nuclearmiRNA processingmachinery and the
destabilizing effects of miRNA processing on RNA genomes. However,
at least in theory, neither of these barriers is insurmountable
(discussed in detail below).
If viruses that replicate in the cytoplasm (e.g. Pox, Picorna, and
Flavi) are to encode miRNAs, they will necessarily have to bypass the
need for nuclear Microprocessor cleavage. Two ways this could
happen include: 1) These viruses could encode a protein with a
Drosha-like function (of note, although no virus-encoded miRNA-
processing proteins have yet been described, the principal hypoth-
esis is supported by the recent identiﬁcation of a Closterovirus-
encoded RNAse III homolog even though this protein has a different
function in inhibiting host RNAi activity (Kreuze et al., 2005)), and 2)
miRNA-like molecules could be produced by transcripts whose ends
come together to form a stem loop structure that is cleaved directly
by Dicer. In support of this later scenario is the existence of
endogenous mirtrons, short introns generated by canonical splicing
of pol II-derived transcripts, that form a hairpin structure which
mimics a Drosha product (Okamura et al., 2007; Ruby et al., 2007).
Additionally, adenovirus expresses miRNA-like molecules that are
derived from the pol III transcribed VA RNAs, which fold into
structures that are processed by Dicer but not Drosha (Andersson et
al., 2005; Lu and Cullen, 2004). While in both of these examples, the
RNAs are initially transcribed in the nucleus, they nonetheless
support the possibility that short RNAs transcribed in the cytoplasm
could directly interact with Dicer to be processed into functioning
miRNAs. Of note, since they bypass the microprocessor, such
structures need not display the fundamental structural features of
canonical pre-miRNA hairpins. This concept is exempliﬁed by the fact
that the VA RNAs represent a multi-stem structure that only mimics
the basal part of a bona-ﬁde pre-miRNA stem, including the typical
3′-OH overhang required for Exportin 5 transport and Dicer cleavage.
Consequently, if such miRNA mimics exist in RNA viruses, they may
well be missed by any prediction algorithm trained to pick up typical
pre-miRNA stem-loops.
Viruses with RNA genomes may be at a ﬁtness disadvantage if
they were to encode regions that are prone to endonucleolytic
cleavage by either Dicer or Drosha. For example, this could result in
reductions in genome/antigenome copy number, or mRNA produc-
tion. In spite of this theoretical barrier, retroviruses, a ﬂavivirus, and
inﬂuenza can be engineered to express biologically active miRNAs or
miRNA-likemolecules (Rouha et al., 2010; Shapiro et al., 2010; Varble
et al., 2010). Notably, because ﬂaviviruses have a lifecycle that is
restricted to the cytoplasm, Drosha-independent mechanisms must
exist to produce these miRNA-like small RNAs. Thus, at least in a
laboratory setting, it is clear that viruses with RNA genomes can
express miRNAs (or miRNA-like molecules) and still be grown to
reasonably high titers.
Finally, we note that some viruses that would seem perfect
candidates for encoding miRNAs apparently do not. Deep sequencing
of small RNAs from human trigeminal ganglia infected with both
Varicella Zoster Virus (VZV) and Herpes Simplex 1 (HSV-1) readily
identiﬁed HSV-1 miRNAs but failed to uncover any VSV miRNAs
(similar to the HSVs, VZV is also a neurotropic alpha herpesvirus most
well known for causing chickenpox and shingles) (Umbach et al.,
2009). A previous computational analysis (Pfeffer et al., 2005) also
suggested VZV may not encode pre-miRNAs (it should, however, be
noted that this analysis was performed with a stringent prediction
algorithm that also missed several authentic pre-miRNAs in otherherpesvirus genomes). Taken together, the above may indicate that
possibly some herpesviruses do not encode miRNAs. Similarly, low
throughput sequencing of RNA from human papillomavirus 31
(HPV 31)-infected cultured cells failed to identify any HPV-encoded
miRNAs (Cai et al., 2006a). While neither the absence of
computationally predicted pre-miRNAs nor the inability to detect
mature miRNAs in infected cells rule out with certainty that these
viruses might encode miRNAs, (for example, miRNAs may be only
expressed in tissues where different promoters are active or novel
RNA processing events occur), these results suggest that some
viruses with nuclear replication, DNA genomes, and latent/persis-
tent lifecycles, do not encode miRNAs. If true, then just as some
members of the herpesvirus family do and some do not encode
miRNAs, it remains a formal, albeit purely speculative, possibility
that some strains of papillomaviruses encode miRNAs.
Functions of viral miRNAs
Overview
A primary goal of the ﬁeld is, once a new viral-encoded miRNA is
discovered, to identify its functions and relevant mRNA targets. To
accomplish this, one must weed-out the “bystander” mRNAs, which
can be targeted by a viral miRNA, but provide no ﬁtness advantage to
the virus (Fig. 3). Remember, although expression of both a typical
miRNA as well as a non-natural small RNAs can affect hundreds of
mRNA targets, these target pools are of a fundamentally different
quality: Endogenous miRNAs have co-evolved with their target sites
overmillions of years, and it therefore can be reasonably assumed that
cellular miRNAs are part of complex networks in which many target
interactions are of physiological relevance (Fig. 1). However, such
assumptions cannot bemade for artiﬁcial small RNAs or for miRNAs of
viral origin, as the host is unlikely to evolve andmaintain a network of
targets for a parasite (as discussed later, an exception from this rule
may be viral mimics of cellular miRNAs, or miRNAs which target
special mRNA elements). It is thus likely that, although viral miRNAs
may regulate many transcripts in an experimentally reproducible and
robust manner, a signiﬁcant number of these interactions will
represent the equivalent of “off target” effects of siRNAs. While
readily tolerated during infection, these “neutral selection” negatively
regulated transcripts may provide little insight into the relevant
functions of a miRNA. In addition, as multiple studies have now been
published that implicate viral miRNAs as playing an important role in
maintaining latent/persistent infection (see below), it becomes
imperative that viral miRNAs are studied in relevant model systems
that recapitulate all modes of infection. For some viral-encoded
miRNAs, this necessitates in vivo models. In particular, those viral
miRNAs that function to evade the adaptive immune response
underscore the importance of animal models of infection. Engineered
mutant viruses, defective for miRNA expression, represent a powerful
approach to understanding viral miRNA function. So far, relatively few
viral miRNAs have any identiﬁed mRNA targets with a conﬁrmed
functional role. Even fewer (n=2) have been studied in the context of
a deleted virus in vivo (Dolken et al., 2010; Sullivan et al., 2009). The
ﬁrst in vivo phenotype reported for an engineered miRNA mutant
virus (Dolken et al., 2010) underscores the power of authentic
infection systems, although an understanding of the targets of these
miRNAs remains incomplete (discussed in detail in the “Functions-
ﬁrst screening” section). Ultimately, the marriage of additional
surgical mutant strains with relevant models of infection should be
most informative.
Strategies for determining viral-encoded miRNA function
There are four predominant strategies that have been used to
uncover viral miRNA functions. The ﬁrst three (antisense targets,
Fig. 3. Strategies for determining virus-encodes microRNA function and their relevant targets. Most strategies for determining the function and relevant targets of virus-encoded
miRNAs can be grouped into two different approaches. First, in the “bottom-up” approach, lists of putative targets can be generated by computational methods or by cDNA
expression or RISC association studies, performed in the presence of increased or decreased activity of the miRNA. The challenge from these approaches is to glean the function of
these miRNAs in the context of infection. To accomplish this, onemust weed out the “bystander” targets from the functionally relevant targets. The second approach, the “top-down”
approach, involves ﬁrst determining whether a virus-encoded miRNA affects a virologically relevant function, and then to use this information to help identify the relevant target(s).
The challenge with such an approach is developing relevant functional screens that can accommodate a reasonable amount of throughput.
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RISC pull down), describe “bottom-up” approaches, whereby candidate
targets are ﬁrst identiﬁed, conﬁrmed, and then dissected to predict
function (see Fig. 3). The fourth, describes a “top-down” approach,
whereby phenotypes or putative functions are ﬁrst identiﬁed, con-
ﬁrmed in the context of infection, and then utilized to identify relevant
targets. Bottom-up approaches can be particularly advantageous as a
starting point in the absence of any preconceived hypotheses of
function. However, each bottom-up strategy can have drawbacks.
Antisense transcripts sometimes are not regulated in a siRNA-like
manner (see below), and computational and comparative cDNA
expression studies suffer from false positives and neutral “bystander”
targets that are indeed targeted by the miRNA of interest, but provide
no selective advantage to the virus (“hitching a ride,” so to speak, with
the functional targets that are drivers of selection). Finally, “functions-
ﬁrst” strategies are a powerful approach when a particular viral-
advantageous function is suspected and readily assayed with reason-
able throughput. However, this approach also has drawbacks— such as
the possibility of investing a large commitment of resources and time
and coming upwith a screen that produces no new insight into the viral
miRNA of interest. Obviously, all four strategies represent only starting
points to advance hypotheses. Ideally, models emerging from these
strategies must be tested in the context of infection in a relevant cell
type. Listed below are examples of viral miRNA functions gleaned from
each strategy. An overview of known targets of cellular or viral targets is
given in Tables 2 and 3, respectively (please note that, with a few
exceptions, we have listed only targets conﬁrmed minimally by
demonstrating that target sites confer repression in reporter assays,
that mutation of the target site alleviates repression and, for cellular
targets, that endogenous protein levels are down-regulated upon
ectopic miRNA expression). The columns labeled ‘Lead’ indicate
whether computational prediction or cDNA proﬁling via microarrays
or RISC pull down was used to identify candidates, or whether aninformed approach was used to analyze a speciﬁc subset of suspected
targets, e.g. antisense transcripts or cellular or viral genes known to be
implicated in certain cellular processes such as apoptosis.
Antisense regulation of mRNA targets
Perhaps the most straightforward examples of determining viral
miRNA function occur when a viral miRNA is encoded on the opposite
strand of a coding mRNA transcript. In this situation, the miRNA
would be predicted to result in a siRNA-like cleavage of the target
mRNA if both are co-expressed. miRNAs with perfect complementar-
ity targets are commonly found in plants, but for incompletely
understood reasons, this strategy is rarely utilized in animals (Bartel,
2004). Interestingly, numerous animal virus miRNAs have been
identiﬁed that are encoded with perfect complementary, antisense
to protein-coding transcripts. Notably, the ﬁrst report describing a
viral miRNA showed that EBV encodes a miRNA (miR-BART2)
complementary to the BALF5 polymerase-coding transcript (Pfeffer
et al., 2004). Two other studies, one that pre-dated this discovery
(Furnari et al., 1993), and one subsequent study (Barth et al., 2008),
lend support to the model that EBV miR-BART2 cleaves the
polymerase-encoding transcript. Since the polymerase encoded by
BALF5 is part of the lytic lifecycle (gamma herpesviruses recruit
cellular polymerases to replicate their genomes during latency) it has
been proposed that the negative regulation by miR-BART2 may
promote latent infection. However, as BALF5 is efﬁciently silenced at
the transcriptional level in latently infected cells, the functional
relevance of the cleavage event remains enigmatic; perhaps it serves
as a second line defense against untimely BALF5 expression.
Interestingly, the closely related rhesus lymphocryptovirus (rLCV)
encodes an orthologous miRNA that has diverged in sequence (Walz
et al., 2010). Due to its conserved location, however, it is expected to
have retained the ability to cleave the antisense-transcribed BALF5
transcripts.
Table 2
Cellular targets of viral miRNAs.
Target Virus miRNA(s) Proposed function Conﬁrmationa Lead Reference(s)
PUMA EBV miR-BART5 Anti-apoptotic 1,2,3,5 Prediction Choy et al., 2008
SMAD2 MDV1 miR-M3 1,2,3 Informed Xu et al., 2010




TWEAKR KSHV miR-K12-10a 1,2,3,4,5 Microarray Abend et al., 2010
BCLAF1 KSHV miR-K5 Inhibit caspase, may facilitate lytic cycle 1,2,3,4,5 Microarray Ziegelbauer et al., 2009
miR-K9
miR-K10a/b
MICB hCMV miR-UL112 Immune escape 1,2,3,4 Prediction/informed Stern-Ginossar et al., 2007
KSHV miR-K12-7
EBV miR-BART2-5p Nachmani et al., 2009
CXCL16 mCMV miR-M23-2 1,2,3,6 Informed Dolken et al., 2010
CXCL-11 EBV mir-BHRF1-3 Immune modulation 5 Informed Xia et al., 2008
p21 KSHV miR-K1 Prevent cell cycle arrest 1,2,3,5 Microarray Gottwein and Cullen, 2010
CCNE2 hCMV miR-US25-1 Block cell cycle to prevent apoptosis? 1,2,3 RISC/miRNA pull down Grey et al., 2010
H3F3B 1,2
TRIM28 3,4
C/EBPbeta p20 (LIP) KSHV miR-K12-3 Paracrine growth promotion? 3 Informed/prediction Qin et al., 2010
miR-K12-7
Gemin8 KSHV miR-K12-4-3p ? 1,2,3 RISC pull down Dolken et al., 2010
BACH1 KSHV miR-K12-11 Mimics cellular miR-155 1,2,3 Microarray Skalsky et al., 2007
Fos 1,2,3,5 Gottwein et al., 2007
PU.1 MDV1 miR-M4 1,2,3 Informed Zhao et al., 2009
GPM6B RREB1 c-Myb
MAP3K7IP2 PU.1 C/EBP
MDV1 miR-M4 1,2 Informed/prediction Muylkens et al., 2010
Rbl2 KSHV miR-K12-4-5p Increased DNA methylation? 1,2,3 Informed Lu et al., 2010b
MAF KSHV miR-K12-1 Trans-/de-differentiation 1,2,3,4,5 Microarray/prediction Hansen et al., 2010
miR-K12-6-5p
miR-K12-11
IkappaB-alpha KSHV miR-K12-1 Promote latency 1,2,3,4,6 Informed Lei et al., 2010
NFIB KSHV miR-K12-3 1,2 Prediction Lu et al., 2010a
Dicer EBV miR-BART6 1,3 Prediction Iizasa et al., 2010
a Numbers indicate that the following observations were made: upon ectopic miRNA expression (1) luciferase reporters and/or target protein expression constructs are repressed
and (2) target sitemutation in luciferase reporters and/or expression constructs leads to de-repression. (3) Endogenous protein levels are down regulated upon ectopic expression of
the miRNA or upon (4) de novo infection with live virus. In infected cells, treatment with speciﬁc (5) miRNA inhibitors results in up-regulation of endogenous protein levels. (6)
Knockout virus mutants were investigated in vivo or in vitro.
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DNA genomes, associated with several human diseases in immuno-
compromised patients with clinical outcomes including tumorigen-
esis, organ rejection, and dementia), encode miRNAs late during lytic
infection that are complementary to the early transcripts (Cantalupo
et al., 2005; Seo et al., 2009, 2008; Sullivan et al., 2005, 2009). miRNAs
from four different polyomaviruses, including Simian Virus 40 (SV40),
JCV, BKV, and murine Polyomavirus (muPyV) have been shown to
direct the cleavage of the early transcripts that encode the large and
small tumor antigen (T antigen) proteins (Seo et al., 2009, 2008;
Sullivan et al., 2005, 2009). Additionally, Merkel Cell Polyomavirus
(MCV) encodes a miRNA that is complementary to the early mRNAs,
and negatively regulates reporters that contain portions of the early
mRNAs (Seo et al., 2009). The strongest evidence that this auto-
regulation of viral transcripts is functionally relevant comes from our
studies of a mutant SV40 virus that fails to express the miRNA.
Compared to wildtype, this virus encodes increased early protein
(both large and small T antigens) levels (Sullivan et al., 2005).
Additionally, cells infected with themutant virus aremore susceptible
to in vitro cytotoxic T cell (CTL)-meditated lysis (when co-cultured
with CTL clones reactive for a speciﬁc T antigen epitope). A mutant
strain of muPyV, dl1013, does not produce the viral miRNA due to a
small deletion. Like the SV40 miRNA mutant, dl1013 expresses
increased levels of the T antigen protein (compared to wild type
virus) during infection of cultured cells (Sullivan et al., 2009).
Furthermore, like SV40, early transcript cleavage fragments aredetectable that bear the molecular hallmarks of miRNA-mediated
RISC cleavage. However, both the SV40 mutant and the muPyV
mutant viruses replicate to wild type levels in cultured cells. These
data argue that despite being preserved in laboratory strains
throughout decades of passage, the functional role of the miRNA is
not essential for infection of cultured cells. Furthermore, infection of
mice with miRNA mutant muPyV shows an indistinguishable
phenotype from wild type virus in assays of acute infection and CTL
reactivity in vivo. Thus, while the conserved nature of the miRNA-
mediated autoregulation of the T antigens in diverse members of the
Polyomaviridae suggests an important role in the virus lifecycle, it
seems this role is not measurable by standard assays of laboratory
infection. The muPyV miRNA example, which is the ﬁrst viral miRNA
to be studied in a mutant context in vivo, lends support to the notion
that the functional roles of viral miRNAs are likely to serve as a subtle
regulators — similar to their host counterparts. Ongoing experiments
revolve around assaying for differences in persistence, shedding, and
transmission of the muPyV miRNA mutant.
Although at least four well-characterized viral miRNAs that direct
cleavage of complementary mRNA targets exist (Barth et al., 2008;
Pfeffer et al., 2004; Seo et al., 2008; Sullivan et al., 2005, 2009), there
are interesting exceptions to this mode of antisense regulation. In
HSV-1 infection, miR-H2-3p is encoded antisense to ICP0 (an
immediate early transcription factor involved in initiating full
progression of lytic replication). However, miR-H2-3 does not direct
cleavage of this mRNA transcript (Umbach et al., 2008). Indeed, miR-
Table 3
Viral targets of viral miRNAs.
Target Virus miRNA(s) Proposed function Conﬁrmationa Lead Reference(s)
LT-Ag SV40 miR-S1 Contribute to immune evasion by limiting
viral antigen expression?
3,5 Informed Sullivan et al., 2005
JCV miR-J1 1,3,4
BKV miR-B1 1,3 Seo et al., 2008
PyV miR-P1 3,4,5 Seo et al., 2009
MCPyV miR-M1 1 Sullivan et al., 2009
LMP-2a EBV miR-BART22 1,2 Prediction Lung et al., 2009
LMP1 EBV miR-BART1-5p Prevent apoptosis 1,2 Informed Lo et al., 2007
miR-BART16
miR-BART17-5p
BALF5 EBV miR-BART2 Prevent lytic replication/promote latency 1,2,3 Informed Barth et al., 2008
RTA KSHV miR-K9* 1,2,4 Informed Bellare and Ganem, 2009
IE72 (UL123, IE1) hCMV miR-UL112-1 1,2 Prediction Grey et al., 2007
UL114 hCMV miR-UL112-1 1,2,5 Informed Stern-Ginossar et al., 2009
ICP0 HSV-1 miR-H2-3p 1,2 Informed Umbach et al., 2008
ICP34.5 HSV-2 miR-2 1,2 Informed Tang et al., 2009
ICP0 miR-3
UL28 MDV1 miR-M4 1,2 Prediction Muylkens et al., 2010
UL32
IE1 hCMV miR-UL112-1 Modulate lytic replication 1,2,5 Prediction Murphy et al., 2008
ICP34.5 HSV-2 miR-1 Control neurovirulence 1 Informed Tang et al., 2008
DNA polymerase I HvAV miR-1 Regulate viral replication 1 Informed Hussain et al., 2008
a Numbers indicate that the following observations were made: upon ectopic miRNA expression (1) luciferase reporters and/or target protein expression constructs are repressed
and (2) target site mutation in luciferase reporters and/or expression constructs leads to de-repression. In infected cells, (3) speciﬁc cleavage products are observed for miRNAs that
are antisense to their proposed target. Inhibition of authentically expressed miRNAs in infected cells via speciﬁc (4) miRNA inhibitors results in up-regulation of the target.
(5) Knockout virus mutants were investigated in vivo or in vitro.
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scripts, but does so in a manner that does not result in turnover of the
mRNA transcript. The mechanism for how this occurs is currently
unknown. In addition, HCMV miR-UL112 is encoded antisense to and
with perfect complementarity to the viral UL114 transcript encoding
DNA glycosylase (Grey et al., 2005; Pfeffer et al., 2005). Stern-Ginossar
et al. report that ectopic expression of miR-UL112 prior to infection
(with a virus expressing an epitope-tagged version of UL114), results
in reduced protein levels of tagged UL114 during infection (Stern-
Ginossar et al., 2009). It should be noted that these experiments did
not examine whether a speciﬁc cleavage event was detectable in the
tagged UL114 transcript, and the decrease observed could be partially
explained by pleiotropic effects of other viral transcript targets of
miR-UL112 (Grey et al., 2007). However, despite perfect complemen-
tarity of miRNA and target as well as robust expression of both mRNA
and miRNA transcripts during acute infection, Grey and Nelson report
that mRNA cleavage is not observed, even though reporters
engineered with a perfect complementary site to miR-UL112 are
susceptible to negative regulation (Grey and Nelson, 2008). For these
reasons, Grey and Nelson speculate that the secondary structure of the
regions ﬂanking the miR-UL112 complementary site in UL114 might
act to prevent cleavage. This strategy could allow a virus to encode
miRNAs antisense to mRNA transcripts without altering viral gene
expression from transcripts lying on the other strand. While key
questions remain, these combined results suggest that in some
contexts, miR-112 may be able to direct negative regulation of UL114,
perhaps in a cleavage-independent manner, similar to HSV miR-H2-3
and ICP0. Future studies regarding the activities of miR-H2-3p and
miR-UL112 should be informative not only to herpes virus gene
regulation, but also more broadly to the optimal design of small
interfering RNAs (siRNAs).
Finally, we note that there are several additional examples where
virus-encoded miRNAs negatively regulate perfectly complementary
mRNA targets, but it is not yet clear if this regulation is due to siRNA-
like cleavage (Tang et al., 2008; Xia et al., 2008). Of particular interest
is a host target, CXCL-11. As shown from miRNA inhibition studies
in infected cells, EBV-miR-BHRF1-3 negatively regulates CXCL-11
(Pfeffer et al., 2004; Xia et al., 2008). Because CXCL-11 is an interferon-inducible, pro-immunomodulatory cytokine, this example might
represent an immune evasion strategy of the virus that is also
relevant to EBV-associated tumorigenesis. Although one may have
expected that more viral miRNAs might have evolved perfect
complementarity towards their target, so far, CXCL-11 is the unique
example of a viral miRNA that has adopted this strategy.
Computational identiﬁcation of miRNA targets
A rapid method for formulating hypotheses as to the targets/
functions of a virus-encoded miRNA is to use one of several popular
target prediction programs (Enright et al., 2003; Kertesz et al., 2007;
Kiriakidou et al., 2004; Krek et al., 2005; Lewis et al., 2003; Miranda
et al., 2006; Rehmsmeier et al., 2004). Almost all of these algorithms
operate on the common principle that target recognition should occur
primarily through binding of the seed region; hence they search for
transcripts with regions that are complementarity to this 6–7 nt
signature. Although most algorithms also consider additional para-
meters (e.g. auxiliary base pairing of distal miRNA sequences,
sequence context or structural accessibility of the target site) to
rank the putative targets, because of the rudimentary understanding
of the molecular events which govern target recognition, all suffer
from rather large numbers of false positive predictions. For cellular
miRNAs, the by far most effective means to distinguish functional
target sites from false positives is consideration of evolutionary
conservation: asmany of themiRNAs are conserved between different
species, so are their target sites. However, as discussed above, because
the host is unlikely to conserve target sites for the beneﬁt of a virus,
such a ﬁlter would only have utility for the minority of virus miRNAs
that may mimic evolutionary conserved host miRNAs. This likely
accounts for the fact that, although computational approaches have
been used with great success for identifying host miRNA–target pairs,
there are far fewer examples of un-informed bioinformatic predic-
tions yielding functional insights into virus-encoded miRNAs. Never-
theless, some notable exceptions exist in which this approach was
utilized successfully (see below).
Computational prediction identiﬁes host-encoded targets. To our
knowledge, there are only three examples in which cellular targets
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functional or phenotypic leads. The ﬁrst is the p53 up-regulated
modulator of apoptosis (PUMA), a pro-apoptotic factor which is
repressed by the EBV-encoded miR-BART5 (Choy et al., 2008). PUMA
was identiﬁed as a top-ranking target of miR-BART5 by the RNAhybrid
(Rehmsmeier et al., 2004) and miRANDA (Enright et al., 2003)
algorithms. Lending support to the idea that the observed repression
is of physiological relevance is the observation that PUMA expression
levels are low in nasopharyngeal carcinoma (NPC), an EBV-positive
tumor that expresses high levels of the BART-miRNAs. Speciﬁc
inhibition of miR-BART5 in tumor-derived cell lines furthermore
leads to apoptosis, and this phenotype can be partially reversed by
introducing a siRNA directed against PUMA. Hence, at least in NPC,
miR-BART5 may contribute to tumorigenesis by antagonizing apo-
ptotic stimuli resulting from constitutive transcription of the PUMA
locus. The authors also note that the target site in the PUMA transcript
is conserved in other vertebrate species; however, as this is not a
cellular target site, for the reasons discussed above, this observation
alone does not allow any conclusions as to its functional importance. It
is, however, interesting to note that the related rLCV encodes a miR-
BART5 orthologue (miR-rL1-8) has a conserved seed sequence (Cai et
al., 2006b), and therefore would be expected to repress PUMA
expression in its natural host, the rhesus macaque. A recent study,
however, observed that miR-rL1-8 was unable to repress the 3′-UTR
of the rhesus transcript, indicating that this function in fact may not be
a conserved feature of miR-BART5 (Riley et al., 2010).
The second example is the identiﬁcation of the major histocom-
patibility complex class I-related chain B (MICB) transcript as a target
for the Human Cytomegalovirus (HCMV)-encodedmiR-UL112 (Stern-
Ginossar et al., 2007). MICB was predicted as a top target by the
RepTar algorithm (Stern-Ginossar et al., 2007) andwas conﬁrmed as a
direct target of miR-UL112 using luciferase assays. Importantly,
endogenous protein levels of MICB are down-regulated by ectopic
miR-UL112 overexpression as well as by infection with live virus,
whereas a mutant virus defective for miR-UL112 expression also fails
to repress MICB. MICB is a stress-induced ligand of the natural killer
(NK) cell activating receptor NKG2D; its repression would be
predicted to be of great beneﬁt for HCMV as the protein is critical
for the elimination of virus-infected cells by NK cells. Indeed,
ﬁbroblasts infected with miR-UL112 defective virions not only fail to
downregulate MICB but are also much more susceptible to NK-cell
mediated cytotoxicity, further underlining the functional relevance of
these ﬁndings. In a surprising twist, by systematic functional testing of
EBV and KSHVmiRNAs, Nachmani et al. later showed that EBV as well
as KSHV also express miRNAs with the ability to suppress MICB
expression (Nachmani et al., 2009). Since the active miRNAs do not
show any sequence homology and also engage different target sites
within the MICB transcript, this would mean that several viruses have
independently evolved mechanisms to counteract this important
mediator of innate immunity.
The last example of bioinformatically predicted targets is a study
that used the DIANA-microT program (Kiriakidou et al., 2004) to
identify the miRNA-processing enzyme Dicer as a target of the EBV-
encoded miR-BART6-5p (Iizasa et al., 2010). Although 3′-UTR
luciferase reporters as well as endogenous Dicer levels are repressed
by ectopic miR-BART6 expression, the functional consequences of this
regulation remain unclear. Downregulation of Dicer would be
expected to result in a widespread repression of miRNAs, which
indeed transient overexpression of miR-BART6-5p in HeLa cells seems
to induce. Whether miR-BART6-5p also leads to similar changes in
authentically infected cells is unknown. The authors argue that a
recent study which has reported global down-regulation of host-
miRNAs in de novo-EBV infected cells (Godshalk et al., 2008) argues
for this possibility; however, this study used the B95-8 strain of EBV,
which lacks the entire miR-BART6 precursor due to a large deletion.
Nevertheless, Iizasa et al. show that introduction of an antagomir(chemically modiﬁed speciﬁc antisense oligonucleotide miRNA
inhibitor) against miR-BART6-5p into latently infected cells leads to
upregulation of several latent and lytic genes, which may point
towards an important role of this miRNA in the regulation of viral
latency.
Computational prediction identiﬁes virus-encoded targets. In spite of the
disadvantage of using computational prediction with mostly non-
evolutionarily conserved viral miRNAs, there is at least one advantage
to studying viral-encoded targets of miRNA — there are substantially
fewer potential targets that are encoded by viral genomes. A study by
Grey et al. was one of the ﬁrst to utilize this strategy with success on a
miRNA encoded by HCMV (Grey et al., 2007). Using a computational
strategy that relied in part on comparing putative HCMV miRNA
targets to similar targets in the chimpanzee, Grey et al. show that miR-
UL112-1 target three viral transcripts. Lending credence to the
functional relevance of this observation, exogenous pre-expression
of miR-UL112-1 results in reduced virus replication. Thus, some viral
miRNAs function to autoregulate viral gene expression. Interestingly,
this same miRNA also negatively regulates a component of the
host innate anti-viral immune response (discussed in the previous
section).
Currently, there are two examples of insect viruses that encode
miRNAs, Bombyx mori nucleopolyhedrosis virus (BmNPV) and
Heliothis virescens ascovirus (HvAV). BmNPV is a member of the
baculovirus family, whose members are DNA viruses and include
those that have been developed for possible use as biopesticides, and
more recently, have been utilized to grow abundant amounts of
recombinant, post-translationally modiﬁed eukaryotic proteins. Four
BmNPV miRNAs have been identiﬁed using computational and deep
sequencing approaches (Singh et al., 2010). All BmNPV miRNAs are of
unknown function. HvAV is a member of the ascovirus family.
Ascoviruses have DNA genomes, infect invertebrate insects, and are
evolutionarily distantly related to the Iridoviridae. Bioinformatic
analysis was used to identify the viral DNA polymerase as a target
of HVaV-miR-1(Hussain et al., 2008). Similar to HCMV miR-UL112-1,
exogenous pre-expression of this miRNA results in reduced virus DNA
replication. Thus, divergent virus families utilize virus-encoded
miRNAs to autoregulate gene expression. The likely functional
importance of autoregulation of viral gene expression is further
discussed below (see “Lessons learned” section).
cDNA proﬁling to identify mRNA targets
There have been numerous studies that have utilized cDNA
expression proﬁling to identify viral miRNA targets. In this approach,
a viral miRNA of interest is either exogenously expressed or has its
function blocked or removed (by antisense inhibitors or mutation
within the virus genome). Cells are then either directly proﬁled for
changes in mRNA steady state levels, or alternatively, some
component of the RISC complex is precipitated, and changes in the
levels of mRNAs recruited to the RISC are assayed. The subset of
differentially regulated/precipitated transcripts is then interrogated
for the presence of potential target sites using computational
methods. This approach represents an excellent beginning strategy,
particularly when no functional insights regarding a particular
miRNA's function are suspected. However, divining functions from a
long list of candidate targets often requires extensive additional
experiments. Therefore, conﬁrmatory experiments are usually per-
formed only on a small subset of the originally identiﬁed candidates.
Most often such candidates are selected because they are suspected to
be of importance for the viral lifecycle, such as for example known
pro-apoptotic factors or genes that are involved in immune responses.
While it is reasonable to assume that such transcripts represent the
most relevant targets among the candidates, one should keep in mind
that this also introduces a strong bias in an otherwise unbiased cDNA
expression or RISC screening approach. In the following section we
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particular emphasis on those that provide functional insights in the
context of infection.
A recent study from Grey et al. used two different positive
enrichment strategies to identify mRNA targets of miR-US25-1, one of
the most highly expressed miRNAs made during HCMV lytic infection
(Grey et al., 2010). Here, a stable cell line expressing an epitope-
tagged component of RISC (Myc-Argonaute 2) was used in conjunc-
tion with a construct that expresses miR-US25-1. Additionally, a
biotinylated synthetic mimic of miR-US25-1 was used to pull out
RISC-bound transcripts. This combined strategy identiﬁed numerous
(approximately 15) transcripts that scored in both assays. Many of the
targets play a role in cell cycle control, such as cyclin E2. Perhaps the
most striking ﬁnding from this study was that most of the target
transcripts are bound by RISC in their 5′ UTRs. Chimeric luciferase
reporters conﬁrmed direct regulation of the 5′ UTRs of two transcripts
including cyclin E2. This is the ﬁrst report of a virus miRNA targeting
the 5′UTR of an mRNA, and opens the possibility that other miRNAs
(host or viral) may utilize a similar mechanism. Importantly, infection
with wild type virus results in increased recruitment of the cyclin E2
transcript to RISC, and infection with a miR-US25-1 deletion mutant
virus results in higher levels of cyclin E2. Although most of the
remaining targets await experimental conﬁrmation, the identiﬁcation
of multiple targets involved in a single process such as cell cycle
regulationmakesmiR-US25-1 unique amongst the other viral miRNAs
with known functions. Most virus-encoded miRNA are expected to
regulate one or a few targets to effect a particular function, or more
rarely, tap into pre-existing host miRNA seed-target networks
(discussed in depth in the Viral miRNAs — tapping into host miRNA
regulatory networks? section). As the latter is apparently not the case
for miR-US25-1 (there is no recognizable sequence homology to any
of the currently known human miRNAs), it is tempting to speculate
that miR-US25-1 could exploit the presence of a hypothetical
sequence element that may be common to the 5′-UTR of transcripts
encoding cell-cycle related factors.
The virus with most published reports utilizing cDNA proﬁling to
identify miRNA targets and functions is Kaposi's sarcoma-associated
herpesvirus. As described above, similar to EBV, KSHV infection is
associated with several tumor entities. Unlike EBV, however, KSHV
does not encode a single dominant oncogene, and the virus also does
not exhibit strong transforming activity in vitro. Perhaps reﬂecting
this moremodest behavior in experimental systems, Kaposi's sarcoma
represents a hyperproliferative disease much more than a true
neoplastic tumor (see Ganem, 2010 for more in-depth information
on this disease). The proliferating component in KS lesions are the so-
called spindle cells, cells of endothelial origin which are, for the most
part, latently infected with KSHV. However, these cells require
exogenous growth factors for continued proliferation and survival,
and hence are dependent on a KS microenvironment that is rich in
immunoinﬁltrates and cytokines. Interestingly, cells that undergo
lytic replication release signiﬁcant amounts of cyto- or chemokines as
a result of endogenous host gene expression as well as due to the
expression of host genes that have been captured by the virus. Since a
signiﬁcant proportion of KSHV-positive cells (~1–5%) in KS lesions
undergo lytic replication, it is thought that these lytically reactivated
cells greatly contributes to KS pathogenesis via paracrine mecha-
nisms. Thus, besides the identiﬁcation of host genes that are regulated
by the virus, determining how viral gene products help to maintain
latent infection, and which virus gene products control the switch to
lytic infection is of paramount importance to understanding KSHV-
associated disease.
Indeed, among the cellular KSHV miRNA targets that have so far
been identiﬁed, there are several genes that play a role in the
regulation of the switch from latent-to-lytic infection (see Tables 2
and 3, also discussed below in “Lessons learned” section). In addition,
several targets have been identiﬁed that may play an important role inthe etiology of KSHV-associated disease. For example, Thrombospon-
din is an anti-angiogenic factor frequently mutated in various cancers,
and has previously been found to be downregulated in KS lesions.
Indeed, exogenous expression of 10 of the 12 KSHV miRNAs down-
regulates Thrombospondin levels (Samols et al., 2007), indicating that
multiple KSHV miRNAs cooperate to repress this cellular factor. Given
the highly vascularized nature of KS lesions, it is possible that miRNA-
targeting during latent infection plays a dominant role in mediating
this phenotype. A more recent study identiﬁed the TNF-like weak
inducer of apoptosis (TWEAK) receptor (TWEAKR) as a direct target
of miR-K12-10a (Abend et al., 2010). In addition to demonstrating
repression in luciferase assays, Abend and colleagues also showed that
KSHV infection leads to downregulation of the protein in endothelial
cells. Furthermore, miR-K10a-mediated downregulation of TWEAKR
prevents TWEAK-induced caspase activation, and alleviating TWEAKR
repression in infected cells via a speciﬁc miR-K10a inhibitor reverses
this effect. Interestingly, this repression may not be only beneﬁcial for
the infected cell in which the actual down-regulation occurs, but also
for the surrounding cells: as downregulation of TWEAKR inhibits pro-
inﬂammatory cytokine release by primary endothelial cells in
response to TWEAK treatment, this mechanismsmay serve to dampen
immune responses in KS lesions.
Another example is Bcl2-associated factor (BCLAF1), a protein
that interacts with several different members of the BCL family. Like
the BCL family, it appears that BCLAF1 can have either pro or anti
apoptotic functions. Several KSHV-encoded miRNAs can inhibit
BCLAF1 expression during infection, and under some conditions of
growth for cultured cells, KSHV miRNA inhibition of BCLAF1 can
result in decreased cleavage of PARP-1 (Ziegelbauer et al., 2009).
However, repression of BCLAF1 by the KSHV miRNA does not inhibit
apoptosis, and might function to modulate apoptosis-independent
functions of PARP-1. Interestingly, BCLAF1 expression can foster
decreased lytic activation of cells latently infected with KSHV. Thus,
KSHV miRNAs that target BCLAF1 can alter the balance between
latent/or lytic infection in a pro or inhibitory fashion, at least under
some experimental conditions (discussed in greater detail in the “A
predominant role of viral miRNAs may be during latent or persistent
infection” section). Another example includes the cell cycle regula-
tory protein, p21. P21 is activated by several different signaling
pathways, most notably p53. P21 negatively regulates cell cycle
progression. Gottwein and Cullen have shown that KSHV miR-K12-1
binds to the 3′UTR of p21 mRNA and directs repression of protein
expression (Gottwein and Cullen, 2010). Ectopic expression of this
miRNA can block p21-mediated cell cycle arrest. Importantly, this
repression is functionally relevant in cells latently infected with
KSHV, as inhibition results in a slightly higher percentage of cell that
undergo p21-mediated arrest. Thus, numerous cellular targets of
KSHV miRNAs have been identiﬁed that play a role in the virus
lifecycle and likely in the diseases associated with infection of this
virus.
Two different labs have utilized an array-proﬁling strategy to
demonstrate that KSHV miR-K12-11 has numerous cellular targets
that likely play a role during infection. Compared to the vast majority
of virus-encoded miRNAs, miR-K12-11 is atypical in that it shares
extensive identity (11/22) including a perfect seed match with a host
miRNA (miR-155). Both the Renne and Cullen groups have indepen-
dently shown that ectopic expression of either miR-K12-11 or miR-
155 results in downregulation of a common set of host mRNA
transcripts (Gottwein et al., 2007; Skalsky et al., 2007). Furthermore,
chimeric luciferase reporters containing the 3′UTRs of several of these
targets were used to demonstrate direct regulation. Hence, miR-K12-
11 may have evolved to mimic a cellular miRNA. Because miR-155 not
only plays an important role in B cell development but is also
considered to have oncogenic potential, the implications of these
ﬁndings will be discussed separately in the section Viral miRNAs —
tapping into host miRNA regulatory networks?.
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“Functions-ﬁrst” approaches have the obvious advantage of
starting with an already known phenotype of relevance, preferably
one that has been observed in authentic infectious model systems.
These approaches can be extremely powerful, especially if the
phenotype can be reproduced in vitro. In these cases, individual
miRNAs or combinations thereof can be tested for their ability to
support the phenotype. In the reverse approach, speciﬁc miRNA
inhibitors or mutant viruses that are defective for miRNA expression
can be employed to demonstrate the absence of the phenotype in
infected cells. Cellular or viral factors known to be involved in
particular pathways tied to the phenotype in question can then be
systematically tested for their downregulation by speciﬁc miRNAs. Of
course, depending on the number of suspected factors and the
complexity of the phenotype, the identiﬁcation of the responsible
target transcripts may still represent a challenging task.
A recent example of a “functions-ﬁrst” approach is a study that
investigated KSHV-induced phenotypic changes in endothelial cells
(Hansen et al., 2010). Previous studies had shown that KSHV infection
of primary lymphatic or blood endothelial cells (BEC or LEC,
respectively) induces a transcriptional reprogramming such that the
resulting cells are of an intermediate phenotype and express markers
of both lineages (Carroll et al., 2004; Hong et al., 2004; Wang et al.,
2004). This observation is of interest because the spindle cells in KS
lesions likewise express LEC as well as BEC markers, suggesting that
KSHV induces a partial de- or trans-differentiation. In order to
elucidate the potential role of viral miRNAs during this process,
Hansen and colleagues subjected LECs which had been transduced
with a recombinant lentivirus expressing 10 of the 12 KSHV-encoded
miRNAs to cDNA proﬁling. Analysis of the negatively regulated
transcripts with the PITA algorithm (Kertesz et al., 2007) led to the
identiﬁcation of the cellular transcription factor MAF (musculoapo-
neurotic ﬁbrosarcoma oncogene homolog), which was experimental-
ly conﬁrmed to be a direct target of several KSHV-encoded miRNAs.
Indeed, MAF is expressed in a LEC-speciﬁc manner and suppresses
several BEC markers, hence contributing to LEC identity. Importantly,
not only does authentic KSHV infection of LECs result in the repression
of MAF expression, but the phenotype can also be prevented by
treatment of the infected cells with speciﬁc inhibitors of the viral
miRNAs, or by ectopic expression of a MAF cDNA lacking the miRNA
target sites. Hence, the study by Hansen et al. represents an excellent
example of a “functions ﬁrst” approach in which a phenotype
observed in infected cells could be successfully tied to a distinct
target of virally encoded miRNAs.
The precise miRNA targets that mediate another KSHV-induced
phenotype are less well deﬁned. Qin et al. observed that KSHV
infection or introduction of an expression construct encoding 10
KSHV-encoded pre-miRNAs led to increased release of interleukins 6
and 10 in macrophages (Qin et al., 2010). The authors also identiﬁed
the transcriptional repressor C/EBPbeta p20 (LIP) as a potential target
transcript and demonstrated down regulation of endogenous LIP
levels after ectopic miRNA expression. Although siRNA knockdown of
LIP also led to increased IL-6 and IL-10 release, whether this transcript
is a direct target of KSHV miRNAs, and whether it is indeed repressed
and contributes to cytokine production in KSHV-infected cells
remains unknown. Nevertheless, the ﬁndings by Qin et al. suggest
that viral miRNA-expression in infected monocoytes may contribute
to KS pathogenesis via paracrine mechanisms.
Xu et al. systematically tested miRNAs encoded by Marek's disease
virus 1 (MDV1), a member of the alpha herpesvirus family, for their
ability to inhibit apoptosis (Xu et al., 2010). As further discussed in the
section “Viral miRNAs — tapping into host miRNA regulatory
networks?”, MDV1 is an atypical alpha herpesvirus that can induce
tumors in its natural host. Out of 14 miRNAs known to be encoded by
MDV1, miR-M3 in particular was able to promote cell survival after
cisplatin treatment. The authors used TargetScan (Lewis et al., 2003)to identify promising miR-M3 target candidates, and chose the
transcription factor SMAD2 (mothers against decapentaplegic homo-
logue 2) because of its well-known role in transforming growth factor
(TGF)-beta signaling and apoptosis. Indeed, SMAD2 was conﬁrmed as
a target that is directly repressed miR-M3, and rescue of SMAD2
expression using a construct lacking the target sites also antagonized
the anti-apoptotic effects of the miRNA. The observation that MDV1-
induced splenic tumors displayed markedly lower SMAD2 levels than
non-tumor splenic tissues furthermore corroborates the assumption
that anti-apoptotic functions of MDV1-encoded miRNAs contribute to
tumorigenesis.
Two recent studies have used viral mutants to investigate miRNA
functions in primary in vivo or in vitro infection systems. Dolken et al.
(2010) investigated a mutant of mouse cytomegalovirus (MCMV).
Like HCMV, MCMV encodes a number of miRNAs (see Table 1) that
are, however, not related in sequence (Buck et al., 2007; Dolken et al.,
2007). The authors introduced point mutations in the precursor
sequences of the two most abundantly expressed viral miRNAs, miR-
M23-2 and miR-M21-1. These precursors are transcribed from
opposite strands of the same genomic locus; therefore 5 nucleotide
exchanges were sufﬁcient to simultaneously destroy both hairpin
structures and abrogate mature miRNA expression. Infection of mice
demonstrated that the resultingmutants were speciﬁcally impaired in
their ability to mount a persistent infection in salivary glands.
Furthermore, attenuation was only observed in mice able to mount
an effective natural killer (NK) cell response, and could be reversed by
the combined depletion of natural killer (NK) cells and CD4-positive
(but not cytotoxic/CD8-positive) T-cells. This is especially interesting
considering that MCMV infection in salivary glands is known to be
controlled by the concerted action of the above immune cell types
rather than by cytotoxic T cells (Polic et al., 1998, 1996). Hence, some
MCMV-encoded miRNAs may have evolved to mediate immune
escape in speciﬁc organs. While the molecular basis of the escape
remains to be unraveled (the chemokine CXCL16 was identiﬁed as a
putative target of miR-M23-2, but is unlikely to be solely responsible
for the phenotype), the study by Dölken and colleagues demonstrates
the power of investigating miRNAs functions in the context of an
authentic in vivo infection. It is unlikely that the phenotype would
have been noticed by any other approach.
Another study by Seto et al. (2010) systematically eliminated the
miRNAs of the B95-8 strain of EBV. As discussed above, the fully
transforming B95-8 strain harbors a deletion that removes all but 8 of
the EBV-encoded miRNAs. These miRNAs reside at two different loci:
three (miRs-BHRF1-1 to 3) are found ﬂanking the BHRF1 open reading
frame, whereas ﬁve (miRs-BART-1, 2, 3, 4 and 5) remain at the BART
locus, the region which is affected by the genomic deletion. By
selectively scrambling the genomic sequences encoding only the
mature miRNAs, Seto and colleagues generated surgical mutants
which either lack the BHRF-miRNAs, or in which additionally the
BART miRNAs had been eliminated as well; the latter represents the
ﬁrst herpesviral mutant in which all miRNAs have been summarily
obliterated. While both mutants were principally able to transform
primary B cells in vitro, closer examination revealed that cultures
infected with the mutated viruses consistently contained fewer cells
in S-phase, especially during the early phase of infection. Additionally,
these cells exhibited higher apoptotic rates than those infected with
the parental strain. Since the phenotype was equally observed in both
mutants, this observation argues for an important role of the BHRF1
miRNAs in providing an advantage during the early stages of primary
B cell infection, a phase of the viral lifecycle which is critical for the
establishment of long term latency. So far, however, the cellular
targets that mediate this phenotype are unknown. A surprising
ﬁnding of the study was that neither cells infected with the mutant
lacking all miRNAs, nor with another mutant in which the genetic
deletion of B95-8 cells had been repaired, exhibited altered levels of
lytic replication. This was somewhat unexpected since, as discussed in
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herpesvirus miRNAs in promoting viral latency. The study by Seto et
al. thus may indicate that herpesviruses differ in the extent to which
they employ miRNAs in order to control latency, and underscores the
necessity to investigate viral mutants in relevant infection systems.
Finally, as already discussed above in the Computational identi-
ﬁcation of miRNA targets section and illustrated in Fig. 3, a “functions-
ﬁrst” approach by Nachmani et al. (2009) found that single KSHV and
EBV-encoded miRNAs were able to downregulate the NK cell ligand
MICB, similar to the previously observed repression by a HCMV
encoded miRNA (Stern-Ginossar et al., 2007). Interestingly, the
binding sites in the MICB 3′ UTR were different for all three different
(HCMV, KSHV, or EBV) viral miRNAs, suggesting this is an example of
convergent evolution.
Lessons learned
A predominant role of viral miRNAs may be during persistent/latent
infection
Viruses that can form long-term infections without clearance by
the host immune response are said to be able to establish “persistent”
infections. This ability is crucial to fostering spread of the virus and
various virus families accomplish it via different, and sometimes ill-
deﬁned mechanisms. Viral latency is a form of persistence whereby
the infected cell does not produce any viral progeny; rather, the viral
genome persists in a state of restricted viral gene expression (in its
extreme form, this can occur in the absence of any viral proteins) that
allows (and often also fosters) host cell survival and serves as a
successful immune evasion strategy. During latent infection, the host
cell maintains the viral genome but does not actively produce
infectious virions. A hallmark of latency is its reversibility, occasion-
ally resulting in full viral gene expression and culminating with the
production of infectious virions. The herpesviruses have a well-
deﬁned latent infectious cycle and it is notable that the majority of
viral miRNAs were discovered from cells latently infected with
herpesviruses. This observation argues for a likely important role of
the herpesviral miRNAs in maintaining latent infection.
Multiple studies conducted with KSHV miRNA mutant viruses
have uncovered a role for the KSHV miRNAs in controlling lytic
replication. Both Lei et al. and Lu et al. utilized a similar BAC mutant
strategy in which 10 of the 12 KSHV pre-miRNAs were deleted (Lei
et al., 2010; Lu et al., 2010b). Both studies reported that infection with
these mutant viruses led to an increase in the transcript levels of the
master lytic switch protein, RTA. RTA is both necessary and sufﬁcient
to initiate the full cascade of viral lytic gene expression. Consequently,
cells infected with these mutant viruses had increased expression of
lytic transcripts. Lei et al. further showed a modest, approximately
two-fold increase in virion production in the miRNA mutant, as
measured by qRT-PCR of encapsidated genomes. Both studies
implicate host targets of the miRNAs as playing a role in the increased
lytic phenotypes that are observed. Lei et al. argue for miRNA-
mediated increased NFKappa B signaling, which is known to decrease
the propensity of lytic activation (de Oliveira et al., 2010), while Lu et
al. implicate host DNAmethyltransferases in possibly playing a role in
the phenotype observed. Additionally, Lu and Rana et al. (Lu et al.,
2010a) investigated the ability of KSHV-encoded miRNAs to suppress
expression of RTA. miR-K12-3 was found to be able to suppress RTA
but apparently does not target the 3′-UTR of the viral transcript: The
authors noted that a computationally predicted target of miR-K12-3,
the cellular transcription NFIB (nuclear factor I/B), had been
previously shown to be able to reactivate KSHV (Yu et al., 2007).
NFIB was shown to bind to the ORF50 promoter, and the 3′-UTR of the
transcript furthermore can be directly targeted by miR-K12-3.
However, it is presently unclear to what extent miR-K12-3 con-
tributes to the maintenance of latency in infected cells. In contrast, Lu
et al. also suggest that miR-K12-5 can directly regulate the RTAtranscript via its 3′ UTR. Interestingly, Bellare and Ganem have
reported that a different miRNA, KSHV miR-K12-9*, also can directly
regulate the 3′ UTR of the RTA transcript (Bellare and Ganem, 2009).
The authors systematically tested 17 KSHV-speciﬁc antagomir
inhibitors and observed that only inhibition of miR-K12-9* led to an
appreciable up-regulation of lytic cycle induction in infected cultures;
reporter assays conﬁrmed that miR-K12-9* mediates repression via a
single target site in the 3′-UTR of the RTA transcript. It is unclear why
miR-K12-5 scored in one study and KSHV miR-K12-9* scored in the
other, but robust miRNA-mediated regulation of RTA would clearly
be expected to affect lytic induction. The miRNA-meditated direct
effects on RTA reported in both Lu et al. and Bellare and Ganem are
nevertheless subtle. The mechanisms thus may serve to repress those
few RTA transcripts that are produced at basal level in latently
infected cells. Indeed, we and others, have previously observed that
the RTA promoter carries bivalent histone marks and thus exists in a
pre-activated state throughout latency (Gunther and Grundhoff,
2010; Toth et al., 2010). Such promoters are expected to be especially
sensitive to occasional/stochastic ﬁring, and our ﬁndings hence
support the hypothesis that a post-transcriptional mechanism is
required to counteract low-level RTA transcription during latency. It
should be noted that two other studies have demonstrated that
selective antisense inhibition of a subset of the KSHV miRNAs has the
opposite effect, whereby under these experimental conditions, some
miRNAs actually function to promote lytic replication (Lu et al., 2010a;
Ziegelbauer et al., 2009). Thus, there is much to sort out, such as the
relative contribution of the individual miRNAs, as well as the various
reported host and viral miRNA targets that are most important.
However, it seems likely (as determined from the BAC mutant
studies), that a function of the KSHV miRNAs as a whole, is to
negatively regulate the initiation of lytic replication — at least under
some circumstances (Fig. 4).
As mentioned in the above sections, a particular viral miRNA may
target host transcripts, viral transcripts, and in some cases, both.
Regulation of both host and viral transcripts can play a profound role
in staving off the host immune response and promoting cell survival
in persistently infected cells. Viral miRNAs from three families, the
herpesviruses, the polyomaviruses and ascoviruses can negatively
regulate viral gene expression (autoregulation). This mode of
autoregulation, in theory, can help maintain a persistent infection
by 1.) lowering speciﬁc antigen presentation of the targeted gene
product to the adaptive immune response, or 2.) by preventing
induction of the lytic cycle. For some herpesviruses, a bioinformatic
study suggests that viral autoregulation is a predominant function of
the viral miRNAs (Murphy et al., 2008). The increased propensity of
the KSHV miRNA mutants to enter the lytic replication cycle (as
described above) supports the notion that other herpesviruses likely
utilize viral miRNAs to optimize the decision to switch to lytic
replication. In particular, latent infection with the human herpes
simplex viruses (HSV1 and HSV2) results in expression of several
viral-encoded miRNAs but no viral proteins. Some of these HSV
miRNAs have the evolutionarily conserved ability to downregulate
expression of some viral transcripts required for lytic infection (Tang
et al., 2008; Umbach et al., 2008, 2009). Similarly, pre-expression of an
HCMV miRNA leads to decreased viral DNA replication (Grey et al.,
2007), thus, it is possible that HCMV also utilizes viral miRNAs to
curtail lytic replication. This model might also apply to the
Polyomaviridae. Polyomaviruses form lifelong, persistent infections,
however the exact cell types and the mechanisms involved are poorly
deﬁned. Several members of the polyomavirus family encode miRNAs
that can autoregulate early gene products (the T antigens) (as
described above in the “Antisense regulation of mRNA targets”
section). As the T antigens are required to initiate lytic replication,
inhibiting their function could dampen virus production in some cell
types and thus promote persistent infection in vivo. If this model were
correct, then there would have to be a mechanism in some cellular
Fig. 4. The role of virus-encoded miRNAs in promoting KSHV latency. Mutants of KSHV that delete 10 of the 12 pre-miRNA have an increased potential to undergo spontaneous lytic
replication, thus implicating the KSHVmiRNAs as playing a role in regulating lytic replication (Lei et al., 2010; Lu et al., 2010b). Three different miRNAs encoded by KSHV likely play a
particularly important role in this process. Two miRNAs target the viral-encoded RTA, the master lytic switch transactivating protein that is both necessary and sufﬁcient to trigger
lytic replication in KSHV-infected cells. A third miRNA targets the host-encoded IkappaBalpha, an inhibitor of NF Kappa B signaling. Lower NF Kappa B signaling is associated with
increased lytic activation for several gamma herpesviruses (de Oliveira et al., 2010). Thus, KSHVmiRNA-mediated inhibition of an inhibitor of NF Kappa B promotes latency. We note
a few KSHV miRNAs also play a “anti-lytic induction” role in some contexts (Lu et al., 2010a; Ziegelbauer et al., 2009) (not depicted). miRNA–RISC complexes and mRNAs are
depicted as described in the legend for Fig. 1. In the cartoon for latently-infected cells, the viral episome is depicted as circle attached to the chromosome.
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that is independent of the late protein products (which would be
immunogenic and toxic if expressed in persistently infected cells).
Currently, this topic is the subject of ongoing studies (AG and CSS,
unpublished observations). On the other hand and in contrast to
KSHV, an EBV mutant virus in which all miRNAs were deleted did not
display an increased propensity to undergo lytic replication in
cultured cells (Seto et al., 2010). This suggests that despite the
similarities in lifecycles between the human gamma herpesviruses,
the viral-encoded miRNAs have evolved different functionalities
regarding control of the exit from latency into lytic replication.
Thus, in practice, the exact contribution of viral miRNAs to persistent
infection awaits experiments in the appropriate model system for
each individual virus.
A common role of viral miRNAs in evading host defenses?
Almost all viruses encode accessory proteins that are not directly
involved in the replication process and serve no structural role in the
assembly of virions. Typically, these regulatory proteins are involved
in combating host defenses in the ongoing “cat and mouse” game of
the evolution virus–host interactions. Therefore, it is not surprising
that some viral miRNAs have been associated with similar activities in
preventing host defenses including the cytotoxic T cell response, the
natural killer cell response, and apoptosis (reviewed in Sullivan,
2008). Autoregulatory viral miRNAs could indirectly evade the
immune response by lowering the antigenicity of viral proteins or
the overall amount of virus replication. A possible example of this is
the polyomavirus SV40. Cells infected with an SV40 miRNA mutant
virus were more susceptible (compared to wildtype-infected cells) to
cytotoxic T cell-mediated lysis in vitro (Sullivan et al., 2005). However,
in vivo experiments with a similar miRNA mutant murine Polyoma-
virus (muPyV) failed to detect a similar function (Sullivan et al.,
2009). Thus, it remains uncertain as to the role of polyomaviral
miRNA-mediated autoregulation in vivo. As discussed above, miRNAsencoded by HCMV, KSHV, EBV, and MCMV have been associated with
evasion of the NK cell response. Similarly, divergent herpesviruses
have been shown to encode miRNAs that have anti-apoptotic
functions (see Tables 2 and 3). It seems probable that some of the
remaining virus-encoded miRNAs of unknown function may be
involved in similar immune evasion activities. However, as the
muPyV example demonstrates, it is imperative that ultimately the
relevance of these activities is conﬁrmed in vivo.Conservation of viral miRNAs?
The experimental evidence gathered so far suggests that virally
encoded miRNAs appear to mediate evolutionarily conserved func-
tions (e.g. immune evasion, cell cycle control, defense against
apoptosis, and promotion of latency) in a considerable number of
viral species. Considering this, it is surprising that the miRNAs
themselves show little primary sequence conservation. A notable
exception from this rule is that some miRNAs are conserved between
viral species that also show considerable global sequence identity.
Chief among these are EBV and the related rhesus lymphocryptovirus
(rLCV). Both viruses share similar biological properties (including
their association with lymphomas in their natural host) and, despite
of being separated by more than 13 million years of evolution, have
retained ~60–65% of sequence identity. Out of 25 and 34 pre-miRNAs
known to be encoded by EBV and rLCV, respectively, 22 show
signiﬁcant sequence similarity such that they can be traced back to a
common ancestor (Cai et al., 2006b; Walz et al., 2010). However, only
14 of these also produce mature miRNAs with a conserved seed
sequence. Likewise, the human alpha-herpesviruses HSV1 and 2,
which share approximately 60% sequence identity, encode at least 16
and 18 pre-miRNAs, respectively. Of the 9 precursors that are
recognizably of common origin, 6 produce at least one mature
miRNA species with a conserved seed. In addition, members of the
Polyomaviridae including SV40, SA12, BKV, and JCV all expressmiRNAs
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common ancestor.
We have recently performed a bioinformatic study to interrogate
all fully sequenced gamma herpesvirus genomes for the presence of
further putative candidates, including not only known but also
predicted pre-miRNA hairpins in our analysis (Walz et al., 2010).
This analysis shows that evolutionary conservation of viral pre-
miRNA sequences is indeed rare. At present, it is difﬁcult to
understand what the low degree of conservation among viral
miRNAs means. Clearly, this feature distinguishes viral miRNAs
from their cellular counterparts, which have maintained extensive
sequence identity (in most cases not only limited to the seed) over
millions of years. It is, however, possible that viral miRNAs may have
conserved important functions despite of the absence of sequence
conservation. For example, miRNAs which autoregulate viral gene
expression may have co-evolved with the viral genome and thus,
although (or rather because) having diverged in sequence, still
recognize identical targets. By the same token, miRNAs in viral
species that infect different host species (such as EBV and rLCV) may
have acquired changes in order to maintain complementarity to host
mRNA targets. This hypothesis seems especially attractive since
most viral miRNAs do not mimic cellular miRNAs (see below). While
targets sites for cellular miRNAs are (for the most part) evolution-
arily conserved due to their co-evolution, there should be less or no
evolutionary pressure for the host to maintain a site that is
exclusively used by a viral miRNAs (unless the site has some other,
host-related function which necessitates its conservation). It follows
that it is the viral miRNA itself that would have to undergo adaptive
changes if the target sites changes throughout evolution (not too
unlikely an event considering that most sites are located in the 3′-
UTR of the target transcript). The ultimate proof for above scenario
would be the identiﬁcation of a transcript with homologous but
diverged target sites in related host species (for example humans
and rhesus monkey) that are matched by an equally divergedmiRNA
pair of common origin in viruses that infect those host species (for
example ebv-miR-BART2-5p and rlcv-miR-L1-33 (Walz et al.,
2010)). The observation of such ‘adaptive’ evolution would be a
strong argument for the functional importance of a target; note that
this is different from the recent observation of three unrelated viral
miRNAs encoded by HCMV, EBV and KSHV (all human viruses) that
target MICB via different sites, which would represent a case of
convergent evolution rather than preservation of a function adopted
by a common ancestral miRNA. In fact, the rLCV homologue of the
EBV miRNA (miR-BART2-5p) that targets two sites in the human
MICB transcript (Nachmani et al., 2009) has acquired a nucleotide
change in its seed sequence (Walz et al., 2010). As both target sites
are perfectly conserved in the rhesus genome, the rLCV miRNA thus
may have lost the ability to target this transcript.
Viral miRNAs — tapping into host miRNA regulatory networks?
The observation that several miRNAs of viral origin share
sequences with host miRNAs has received much attention. Clearly,
by emulating host miRNAs viral miRNAs could gain access to the large
and intricate networks of target transcripts maintained by the host
(Fig. 5). If so, it is surprising that there is only one known example of a
an entire pre-miRNAs that has (possibly) been captured from the host
(Waidner et al., 2009), despite of the fact that herpesviruses have
frequently pirated host cell genes and subverted them to their own
purposes. However, a short seed sequence may also have evolved
independently; one would expect that a considerable number of such
viral “mimics” of host miRNAs exist. In fact, a survey of all viral and
host miRNA sequences currently deposited in miRBase (release 16)
seems to support this notion. For example, among the 141 known
miRNAs of human herpes- and polyomaviruses, there are 43 instances
of unique 6mer seed sequences that are shared with human miRNAs
(Fig. 6A, further discussed below). However, given the limitedcomplexity of a 6 nucleotide motif, one needs to consider the
possibility that some seed sharing may occur by chance. A recent
study which has analyzed EBV-encoded miRNAs in nasopharyngeal
carcinoma has taken this consideration into account and has found,
nevertheless, that EBV miRNAs with a shared seed are approximately
2 fold more abundant than expected based on a purely probabilistic
model (Chen et al., 2010). We have performed a similar analysis for all
human herpes- and polyomavirus miRNAs deposited in miRBase and
come to a similar conclusion. We extracted all human miRNA
sequences as well as miRNA sequences of human viruses and, in
each contingent, identiﬁed unique 6mer seed sequences (i.e. nt 2–7 of
thematuremiRNA). As noted underneath the bar graph in Fig. 6A (left
panel), there are 1223 human miRNAs, which all together code for
872 unique seeds (the number of unique seeds is lower since many
cellular miRNAs belong to families that share a common seed). Hence,
of the 46=4096 possible combinations for 6mer seeds, 872/
4096=21% are being used by human miRNAs. In other words, for
any randomly selected 6mer, there is a substantial probability
(p=0.21) that it can also be found in a human miRNA. Accordingly,
when considering the 130 seeds which were used by the 141 viral
miRNAs analyzed, one would expect that a considerable
0.21×130=27 seeds are shared by pure coincidence. However, we
observed that a total of 43 seeds were shared between viral and
human miRNAs, corresponding to a signiﬁcant ~1.6 fold enrichment
over the expected random number (Fig. 6A). We further considered
the possibility that there might be a general or positional bias in the
nucleotide composition of the seed sequences, which could poten-
tially falsify the results as the expected values are calculated assuming
an unbiased composition. Therefore, we generated test sets based on
viral miRNA sequences in which either the seed sequences were
completely randomized (dark blue bars), or in which all nucleotides at
a given position of the viral miRNAs were shufﬂed amongst
themselves, thus preserving any potential bias in sequence compo-
sition (light blue bars). The seeds in the two control sets were then
compared to those of humanmiRNAs. Each test was performed 10,000
times to calculate enrichment mean and standard deviation values. As
shown in Fig. 6A, the enrichment of shared seeds among authentic
viral miRNA sequences was statistically signiﬁcant when compared to
either control set. For comparison, we performed the same analysis
for human and mouse miRNAs (Fig. 6A, right panel); in this case, the
seed enrichment was 2.5 fold and highly signiﬁcant. Interestingly, a
slight enrichment (~1.2 fold) was observed in the shufﬂed test,
indicative of a mild sequence bias that did not, however, affect the
statistical signiﬁcance of seed enrichment among authentic miRNA
sequences.
While theminimalmiRNA seed represents a 6mer, most canonical
target sites pair with an extended seed comprising nucleotides 2–8 of
themiRNA, i.e. a 7mer (Bartel, 2009).We hence repeated our analysis
with such 7mer motifs (Fig. 6B), and observed that, although fewer
(14) viral 7mer seeds are shared with humanmiRNAs, the number is
still signiﬁcantly higher than the 8 expected by pure chance. As
expected, a similar analysis of seeds shared between mouse and
human miRNAs shows a substantially higher (~7 fold) enrichment
over the expected value. Taken together, the above indicates that a
minority of viral miRNAs may indeed have evolved to mimic cellular
miRNAs. However, a signiﬁcant proportion (N50%) of shared seeds
will occur by chance, and the percentage of viral miRNAs that are
conserved is dwarfed compared to the host miRNAs. Hence, in each
case, additional evidence is required before common functionality
can be inferred. So far, compelling evidence only exists in a single
case: that of miR-155, which shares extended seed identity with two
viral miRNAs.
miR-155 mimics — viral analogues of a human oncomir? Seed sharing
between the KSHV-encoded miR-K11 and human miR-155 was ﬁrst
noted in a review article by Nair and Zavolan (Nair and Zavolan,
Fig. 5. A hypothesis: most virus-encoded miRNAs will regulate a target mRNA network substantially different than their host counterparts. With a few rare, important exceptions,
most virus miRNAs are not predicted to tap into existing host miRNA-target regulatory networks (top panel). Some virus-encoded miRNAs have been shown to regulate a fairly large
number of mRNA transcripts involved in a particular process, despite the fact that these miRNAs share no seed sequence identity with host miRNAs. This implies that sometimes,
virus-encoded miRNAs are able to tap into viral-speciﬁc, miRNA–mRNA transcript networks (Middle panel). Finally, we propose the hypothesis that the major function of many
virus-encoded miRNAs will be to regulate a small number of key (host or viral) transcripts (bottom panel). Despite the fact that exogenous expression of such miRNAs will result in
changes in the steady state levels of numerous (~hundreds) of transcripts, only a small minority of these need be of functional relevance and the rest may simply be bystanders.
Parsing out the relevant targets is the major challenge of “bottom-up” approaches (described in Fig. 3).
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proﬁling to demonstrate that ectopic expression of either miR-K12-11
or miR-155 results in downregulation of a common set of host mRNA
transcripts (Gottwein et al., 2007; Skalsky et al., 2007), reviewed in
McClure and Sullivan (2008). Several of the candidates were further
conﬁrmed as direct targets using chimeric luciferase reporters. miR-
155 was originally identiﬁed as the only known functional product of
the bic (B cell integration cluster) gene, a common integration site of
avian leukosis virus (ALV) in virus-induced B cell lymphomas
(Clurman and Hayward, 1989). Since then, miR-155 has been found
to be over-expressed in many lymphomas as well as acute myeloid
leukemia (AML) and solid tumors of the breast, colon and lung (see
Teng and Papavasiliou, 2009 for a recent review on this topic). The
observation that forced expression of miR-155 in B cells orhematopoietic stem cells leads to pre-B-cell lymphoproliferation
which can progress to frank lymphoma and AML-like disease,
respectively, has further bolstered the notion that mir-155 represents
a so-called “oncomiR”, i.e. the functional equivalent of a proto-
oncogene. A major physiological role of miR-155 appears to be in the
hematopoietic compartment, where it shapes the inﬂammatory and
immune response by regulating the activity and differentiation of B
cells, T cells andmacrophages; for example, mice deﬁcient in miR-155
are immuno-compromised and display severe defects in B- and T-
lymphocyte maturation as well as antigen presentation by dendritic
cells (Rodriguez et al., 2007).
Given the above, it is conceivable that KSHV, a virus that naturally
infects B cells, may have evolved a mimic of miR-155, perhaps to
modulate host cell differentiation in order to more efﬁciently gain
Fig. 6. Seed sharing amongst viral and host miRNAs. A, B: Statistical analysis of seed
sharing. We analyzed the sharing of 6mer (nts. 2–7 of the mature miRNA sequence, top
panel) or 7mer (nts. 2–7, bottom panel) seeds between human and human herpes- or
polyomavirus miRNAs (left block of columns in each panel), or for comparison between
human and mouse miRNAs (right block of columns in each panel). All sequences were
curated from the September 2010 release 16 of miRBase. We ﬁrst identiﬁed the total
number of unique seeds in each entity, then calculated the number of shared seeds that
would be expected to occur by mere chance. The red and light green bars show the
relative enrichment of the number of actually observed number of shared seeds over
the calculated expect value. As a control, we performed two tests using random and
shufﬂed seed sequences (dark and light blue columns, respectively; see text for further
details). P-values for the hypothesis that differences between the observed enrichment
and either test set are statistical signiﬁcant (one-tailed hypergeometric test) are
indicated by asterisks (*: pb0.5, ** pb0.1, ***: pb0.01). C: Alignment of the KSHV
encoded miR-K11 (top), human and murine miR-155 (center) and miR-M4 encoded by
MDV1 (bottom). Nucleotides that are conserved between both cellular mir-155
orthologues as well as matching nucleotides in viral miRNAs are shown in white on
black background. Nucleotides in viral miRNAs that match residues that are not
conserved between the cellular mir-155 orthologues are shown black on gray
background. The seed region (nts. 2–8) and the region which is considered to be of
special importance for auxiliary base pairing (nts. 13–16) (Bartel, 2009) are marked
underneath the alignment.
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long-term reservoir of latent infection. Under certain (yet to be
deﬁned) conditions, however, the constitutive expression in latently
infected cells may also promote cellular transformation and hence
result in virally induced tumorigenesis. A striking observation is that
the alpha herpesvirus MDV1, a virus which is associated with
lymphomas in chickens, also encodes a miRNA that shares seed
identity with miR-155 (Morgan et al., 2008). Remarkably, the closely
related MDV2 not only lacks tumorigenic potential, but also a
putative miR-155 mimic (indeed, MDV1 is the only known alpha
herpesvirus with a profound tumor association in its natural host).
As observed for its KSHV-encoded counterpart, several cellular
targets were shown to be commonly regulated by miR-M4 and
cellular miR-155 (Muylkens et al., 2010; Zhao et al., 2009).
Strikingly, although the lymphotropic EBV does not encode a miR-
155 mimic of its own, the viral LMP-1 protein strongly induces
expression of the cellular miR-155 in latently infected B-cells (Gatto
et al., 2008; Yin et al., 2008).
Taken together, although formal proof in animal models is still
missing, the available experimental as well as circumstantial evidence
very strongly argues for an important role of KSHV-miR-K11 and
MDV1-miR-M4 during virus-induced tumorigenesis. The extent to
which these miRNAs phenocopy individual miR-155 functions
remains to be determined and, likewise, although a number of shared
targets of miR-155 and its viral mimics have been identiﬁed,
additional experiments will be required to demonstrate their
functional importance during the normal viral lifecycle as well as
virus-induced disease.Conclusions
While still in the early days of understanding the biology of virus-
encoded miRNAs, much progress has been made in the past few
years. A picture is emerging whereby viral miRNAs will generally
(but not always) undergo transcription and biogenesis similar to
host miRNAs. Those viruses most likely to encode miRNAs will have
DNA genomes, and have a nuclear replication cycle. Unlike host
miRNAs, it seems many virus-encoded miRNAs have evolved to
regulate viral transcripts or small networks of host genes via viral-
speciﬁc miRNA target binding sites. There are, however, notable
exceptions whereby some viral miRNAs will mimic host miRNAs and
likely regulate numerous host transcripts that comprise the network
of genes regulated by a particular host miRNA. While caution is
warranted to ensure that the functions uncovered for virus-encoded
miRNAs are not “pigeon-holed” by pre-conceived notions of viral
gene function, a picture is emerging where common functions of
viral miRNAs across divergent families will include: autoregulation
of virus gene expression, regulation of viral persistence/latency,
alteration of the cell cycle, and avoidance of host defenses. Because a
majority of virus-encoded miRNAs have been indentiﬁed in cells
latently infected with herpesviruses, it is possible that inhibiting
these miRNAs might one day provide a strategy for clearing latent
infections — a “holy grail” of the herpesvirus ﬁeld. A combination of
“bottom-up” and “top-down” approaches will continue to unveil
new putative targets and functions and for viral miRNAs. It is
imperative that these putative functions be validated in a relevant
infectious context. It is striking that, to date, only one example of an
in vivo function for a virus-encoded miRNA has emerged. Thus, a ﬁrm
understanding of some virus-encoded miRNAs awaits the develop-
ment of the appropriate model systems for those viruses. In a
relatively short time frame, virus-encoded miRNAs have added
signiﬁcantly to our understanding of some viruses. In the near
future, this understanding will continue to grow, incorporating new
viruses, new functions, and possibly new insights of therapeutic
relevance.
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